Merck to Acquire Harpoon Therapeutics, Further Diversifying

Acquisition includes HPN328, an investigational delta-like ligand 3 targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors

...

Related Keywords

United States , Canada , Julie Eastland , Harpoon Therapeutics Inc , Drug Administration , Linkedin , Goodwin Procter , Merck Co Inc , Statement Of Merck Co Inc , Nasdaq , Centerview Partners , Exchange Commission , Covington Burling , Merck Research Laboratories , Youtube , Evercore Group , Instagram , Facebook , Twitter , Harpoon Therapeutics , Merck Research , Activating Construct , Hart Scott Rodino Antitrust Improvements Act , Orphan Drug Designation , Looking Statement , Looking Statements , Private Securities Litigation Reform Act , Quarterly Report , Markets ,